Status and phase
Conditions
Treatments
About
This is a study looking at all-trans retinoic acid in combination with standard induction and consolidation therapy in older patients with newly diagnosed acute myeloid leukemia (AML).
Full description
First Induction Therapy:
Cytarabine 100 mg/m² cont. i.v. days 1-5
Idarubicin 12 mg/m² i.v. days 1, 3
ATRA 45 mg/m² p.o. days 4-6, ATRA 15 mg/m² p.o. days 7-28
Second Induction Therapy:
Cytarabine 100 mg/m² cont. i.v. days 1-5
Idarubicin 12 mg/m² i.v. days 1, 3
ATRA 45 mg/m² p.o. days 4-6, ATRA 15 mg/m² p.o. days 7-28
First Consolidation Therapy:
Cytarabine 1000 mg/m² bid i.v. days 1-3
Mitoxantrone 10 mg/m² i.v. days 2, 3
ATRA 15 mg/m² p.o. days 4-28
Second Consolidation Therapy
Etoposide 100 mg/m² i.v. days 1-5
Idarubicin 12 mg/m² i.v. days 1,3
ATRA 15 mg/m² p.o. days 4-28
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal